Company
Xeris Biopharma Holdings
NASDAQ:XERS
Xeris (Nasdaq: XERS) is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. Xeris has three commercially available products; Gvoke®, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis®, the first and only FDA-approved therapy for primary periodic paralysis, and Recorlev® for the treatment of endogenous Cushing’s syndrome. Xeris also has a robust pipeline of development programs to extend the current marketed products into important new indications and uses and bring new products forward using its proprietary formulation technology platforms, XeriSol™ and XeriJect™, supporting long-term product development and commercial success.
32 stories · page 2 of 2
Xeris Biopharma inks research collaboration and option agreement with Horizon Therapeutics
Xeris will use its proprietary formulation technology platform, XeriJect, to develop an ultra-concentrated, ready-to-use, subcutaneous injection of teprotumumab, the first and only medicine approved by the US Food and Drug Administration fo
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatments
The company reported record net product revenue of $29.6 million, up 17% quarter-over-quarter and 31% year-over-year on a pro forma basis
Xeris Biopharma reveals Phase 3 SONICS study data evaluating Recorlev for Cushing's syndrome
The results provide important new evidence in support of Recorlev and will help inform clinicians' decisions and individualization of medical therapy for patients with endogenous Cushing's syndrome, according to Dr Ken Johnson
Xeris Biopharma reports positive topline results from Phase 1 trial of subcutaneous levothyroxine
“The Phase 1 study results offer initial proof of concept that our novel subcutaneous formulation of levothyroxine has the potential to provide patients with a once-weekly dosing, thereby potentially improving treatment adherence, as well a
Xeris Biopharma posts record $25.3M 2Q revenue as commercial product sales take off
The record figure represents a 15% increase from the first quarter and a 34% increase from the second quarter of 2021
Xeris Biopharma notes that its commercialization partner for Ogluo in the UK, EEA, and Switzerland, Tetris Pharma, is to be acquired by Arecor Therapeutics
"Having our ready-to-use glucagon, Ogluo, commercialized in the UK and EEA by Arecor would be a very positive step forward in our view," said Paul R. Edick, Xeris' chairman and CEO